Daubert v. Merrell Dow Pharmaceuticals, Inc, No. 92-102

CourtU.S. Supreme Court
Writing for the CourtBLACKMUN, J., delivered the opinion for a unanimous Court with respect to Parts I and II-A, and the opinion of the Court with respect to Parts II-B II-C, III, and IV, in which WHITE, O'CONNOR, SCALIA, KENNEDY, SOUTER, and THOMAS, JJ., joined. REHNQU
Citation113 S.Ct. 2786,509 U.S. 579,125 L.Ed.2d 469
PartiesWilliam DAUBERT, et ux., etc., et al., Petitioners, v. MERRELL DOW PHARMACEUTICALS, INC
Docket NumberNo. 92-102
Decision Date28 June 1993

509 U.S. 579
113 S.Ct. 2786
125 L.Ed.2d 469
William DAUBERT, et ux., etc., et al., Petitioners,

v.

MERRELL DOW PHARMACEUTICALS, INC.

No. 92-102.
Argued March 30, 1993
Decided June 28, 1993.
Syllabus *

Petitioners, two minor children and their parents, alleged in their suit against respondent that the children's serious birth defects had been caused by the mothers' prenatal ingestion of Bendectin, a prescription drug marketed by respondent. The District Court granted respondent summary judgment based on a well-credentialed expert's affidavit concluding, upon reviewing the extensive published scientific literature on the subject, that maternal use of Bendectin has not been shown to be a risk factor for human birth defects. Although petitioners had responded with the testimony of eight other well-credentialed experts, who based their conclusion that Bendectin can cause birth defects on animal studies, chemical structure analyses, and the unpublished "rea alysis" of previously published human statistical studies, the court determined that this evidence did not meet the applicable "general acceptance" standard for the admission of expert testimony. The Court of Appeals agreed and affirmed, citing Frye v. United States, 54 App.D.C. 46, 47, 293 F. 1013, 1014, for the rule that expert opinion based on a scientific technique is inadmissible unless the technique is "generally accepted" as reliable in the relevant scientific community.

Held: The Federal Rules of Evidence, not Frye, provide the standard for admitting expert scientific testimony in a federal trial.

(a) Frye's "general acceptance" test was superseded by the Rules' adoption. The Rules occupy the field, United States v. Abel, 469 U.S. 45, 49, 105 S.Ct. 465, 467, 83 L.Ed.2d 450, and, although the common law of evidence may serve as an aid to their application, id., at 51-52, 105 S.Ct., at 468-469, respondent's assertion that they somehow assimilated Frye is unconvincing. Nothing in the Rules as a whole or in the text and drafting history of Rule 702, which specifically governs expert testimony, gives any indication that "general acceptance" is a necessary precondition to the admissibility of scientific evidence. Moreover, such a rigid standard would be at odds with the Rules' liberal thrust and their general approach of relaxing the traditional barriers to "opinion" testimony.

(b) The Rules—especially Rule 702 —place appropriate limits on the admissibility of purportedly scientific evidence by assigning to the trial judge the task of ensuring that an expert's testimony both rests on a reliable foundation and is relevant to the task at hand. The reliability standard is established by Rule 702's requirement that an expert's testimony pertain to "scientific . . . knowledge," since the adjective "scientific" implies a grounding in science's methods and procedures, while the word "knowledge" connotes a body of known facts or of ideas inferred from such facts or accepted as true on good grounds. The Rule's requirement that the testimony "assist the trier of fact to understand the evidence or to determine a fact in issue" goes primarily to relevance by demanding a valid scientific connection to the pertinent inquiry as a precondition to admissibility.

(c) Faced with a proffer of expert scientific testimony under Rule 702, the trial judge, pursuant to Rule 104(a), must make a preliminary assessment of whether the testimony's underlying reasoning or methodology is scientifically valid and properly can be applied to the facts at issue. Many considerations will bear on the inquiry, including whether the theory or technique in question can be (and has been) tested, whether it has been subjected to peer review and publication, its known or potential error rate, and the existence and maintenance of standards controlling its operation, and whether it has attracted widespread acceptance within a relevant scientific community. The inquiry is a flexible one, and its focus must be solely on principles and methodology, not on the conclusions that they generate. Throughout, the judge should also be mindful of other applicable Rules.

(d) Cross-examination, presentation of contrary evidence, and careful instruction on the burden of proof, rather than wholesale exclusion under an uncompromising "general acceptance" standard, is the appropriate means by which evidence based on valid principles may be challenged. That even limited screening by the trial judge, on occasion, will prevent the jury from hearing of authentic scientific breakthroughs is simply a consequence of the fact that the Rules are not designed to seek cosmic understanding but, rather, to resolve legal disputes.

951 F.2d 1128 (CA9 1991), vacated and remanded.

BLACKMUN, J., delivered the opinion for a unanimous Court with respect to Parts I and II-A, and the opinion of the Court with respect to Parts II-B II-C, III, and IV, in which WHITE, O'CONNOR, SCALIA, KENNEDY, SOUTER, and THOMAS, JJ., joined. REHNQUIST, C.J., filed an opinion concurring in part and dissenting in part, in which STEVENS, J., joined.

Michael H. Gottesman, Washington, DC, for petitioners.

Charles Fried, Cambridge, MA, for respondent.

Justice BLACKMUN delivered the opinion of the Court.

[509 U.S. 582]

125 L. Ed. 2d 476
113 S. Ct. 2791

In this case we are called upon to determine the standard for admitting expert scientific testimony in a federal trial.

I

Petitioners Jason Daubert and Eric Schuller are minor children born with serious birth defects. They and their parents sued respondent in California state court, alleging that the birth defects had been caused by the mothers' ingestion of Bendectin, a prescription anti-nausea drug marketed by respondent. Respondent removed the suits to federal court on diversity grounds.

After extensive discovery, respondent moved for summary judgment, contending that Bendectin does not cause birth defects in humans and that petitioners would be unable to come forward with any admissible evidence that it does. In support of its motion, respondent submitted an affidavit of Steven H. Lamm, physician and epidemiologist, who is a well-credentialed expert on the risks from exposure to various chemical substances.1 Doctor Lamm stated that he had reviewed all the literature on Bendectin and human birth defects—more than 30 published studies involving over 130,000 patients. No study had found Bendectin to be a human teratogen (i.e., a substance capable of causing malformations in fetuses). On the basis of this review, Doctor Lamm concluded that maternal use of Bendectin during the first trimester of pregnancy has not been shown to be a risk factor for human birth defects.

509 U.S. 583]

Petitioners did not (and do not) contest this characterization of the published record regarding Bendectin. Instead, they responded to respondent's motion with the testimony of eight experts of their own, each of whom also possessed impressive credentials.2 These experts had concluded that Bendectin can cause birth defects. Their conclusions were based upon "in vitro" (test tube) and "in vivo" (live) animal studies that

[125 L. Ed. 2d 477]

found a link between Bendectin and malformations; pharmacological studies of the chemical structure of Bendectin that purported to show similarities between the structure of the drug and that of other substances known to cause birth defects; and the "reanalysis" of previously

[113 S. Ct. 2792]

published epidemiological (human statistical) studies.

The District Court granted respondent's motion for summary judgment. The court stated that scientific evidence is admissible only if the principle upon which it is based is " 'sufficiently established to have general acceptance in the field to which it belongs.' " 727 F.Supp. 570, 572 (S.D.Cal.1989), quoting United States v. Kilgus, 571 F.2d 508, 510 (CA9 1978). The court concluded that petitioners' evidence did not meet this standard. Given the vast body of epidemiological data concerning Bendectin, the court held, expert opinion which is not based on epidemiological evidence

[509 U.S. 584

is not admissible to establish causation. 727 F.Supp., at 575. Thus, the animal-cell studies, live-animal studies, and chemical-structure analyses on which petitioners had relied could not raise by themselves a reasonably disputable jury issue regarding causation. Ibid. Petitioners' epidemiological analyses, based as they were on recalculations of data in previously published studies that had found no causal link between the drug and birth defects, were ruled to be inadmissible because they had not been published or subjected to peer review. Ibid.

The United States Court of Appeals for the Ninth Circuit affirmed. 951 F.2d 1128 (1991). Citing Frye v. United States, 54 App.D.C. 46, 47, 293 F. 1013, 1014 (1923), the court stated that expert opinion based on a scientific technique is inadmissible unless the technique is "generally accepted" as reliable in the relevant scientific community. 951 F.2d, at 1129-1130. The court declared that expert opinion based on a methodology that diverges "significantly from the procedures accepted by recognized authorities in the field . . . cannot be shown to be 'generally accepted as a reliable technique.' " Id., at 1130, quoting United States v. Solomon, 753 F.2d 1522, 1526 (CA9 1985).

The court emphasized that other Courts of Appeals considering the risks of Bendectin had refused to admit reanalyses of epidemiological studies that had been neither published nor subjected to peer review. 951 F.2d, at 1130-1131. Those courts had found unpublished reanalyses "particularly problematic in light of the massive weight of the original published studies supporting [respondent's] position, all of which had undergone full scrutiny from the scientific community." Id., at 1130. Contending that reanalysis is generally accepted by the scientific community only when it is subjected to verification and...

To continue reading

Request your trial
22104 practice notes
  • Food for human consumption: Food labeling— Dietary supplements; effect on structure or function of body; types of statements, definition,
    • United States
    • Federal Register January 06, 2000
    • January 6, 2000
    ...(107.) Many comments argued that the proposed rule ignored the Supreme Court decision in Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). FDA disagrees with these comments. The comments did not explain how the rule was contrary to or even affected by the decision. Daubert ......
  • Ebenhoech v. Koppers Industries, Inc., No. 00-5641(JBS).
    • United States
    • U.S. District Court — District of New Jersey
    • December 24, 2002
    ...arguing that Widas' methodology does not have sufficient reliability under the requirements of Daubert v. Merrell Dow Pharmaceuticals, 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993). (Def.'s Br. at Under the Federal Rules of Evidence, a federal judge must serve as a "gatekeeper" to en......
  • Jarvis v. Ford Motor Co., No. 92 Civ. 2900(NRB).
    • United States
    • United States District Courts. 2nd Circuit. United States District Courts. 2nd Circuit. Southern District of New York
    • October 27, 1999
    ...deferred until after the jury's verdict. Pretrial Hearing of May 18, 1999, pursuant to Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), Transcript p. 241 (hereinafter "Daubert Hearing Tr."). At the end of the presentation of evidence, defen......
  • USA. v. Charley, No. 98-2087
    • United States
    • United States Courts of Appeals. United States Court of Appeals (10th Circuit)
    • August 27, 1999
    ...and experience of [the relevant] discipline.'" Id. At ___, 119 S.Ct. at 1175 (quoting Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 592 (1993)). The trial judge has broad discretion, reviewable for its abuse, "to determine reliability in light of the particular facts and circu......
  • Request a trial to view additional results
22155 cases
  • Ebenhoech v. Koppers Industries, Inc., No. 00-5641(JBS).
    • United States
    • U.S. District Court — District of New Jersey
    • December 24, 2002
    ...arguing that Widas' methodology does not have sufficient reliability under the requirements of Daubert v. Merrell Dow Pharmaceuticals, 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993). (Def.'s Br. at Under the Federal Rules of Evidence, a federal judge must serve as a "gatekeeper" to en......
  • Jarvis v. Ford Motor Co., No. 92 Civ. 2900(NRB).
    • United States
    • United States District Courts. 2nd Circuit. United States District Courts. 2nd Circuit. Southern District of New York
    • October 27, 1999
    ...deferred until after the jury's verdict. Pretrial Hearing of May 18, 1999, pursuant to Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), Transcript p. 241 (hereinafter "Daubert Hearing Tr."). At the end of the presentation of evidence, defen......
  • USA. v. Charley, No. 98-2087
    • United States
    • United States Courts of Appeals. United States Court of Appeals (10th Circuit)
    • August 27, 1999
    ...and experience of [the relevant] discipline.'" Id. At ___, 119 S.Ct. at 1175 (quoting Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 592 (1993)). The trial judge has broad discretion, reviewable for its abuse, "to determine reliability in light of the particular facts and circu......
  • Mo. State Conference of the Nat'l Ass'n for the Advancement of Colored People v. Ferguson-Florissant Sch. Dist., Case No. 4:14 CV 2077 RWS
    • United States
    • United States District Courts. 8th Circuit. United States District Court (Eastern District of Missouri)
    • August 22, 2016
    ...have established by a preponderance of the evidence that his testimony is admissible. See Daubert v. Merrell Dow Pharms., Inc. , 509 U.S. 579, 592 & n. 10, 113 S.Ct. 2786, 125 L.Ed.2d 469 (citing Rule 104(a)) (1993); Fed. R. Evid. 702 ; see also Pls.' Post-Trial Br. at 2-4. I also find that......
  • Request a trial to view additional results
11 firm's commentaries
  • Don’t Say Daubert
    • United States
    • LexBlog United States
    • August 16, 2021
    ...it totally ignores the 2000 overhaul of Rule 702 that “respon[ded]” to the recognition in Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and subsequent cases that federal district judges have “the responsibility of acting as gatekeepers to exclude unreliable expert testi......
  • Ninth Circuit Rejects Challenges To Conjoint Analysis In Consumer Class Action
    • United States
    • Mondaq United States
    • December 30, 2021
    ...569 U.S. 27 (2013), but also that it is inadmissible under Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). But a recent Ninth Circuit decision, MacDougall v. American Honda Motor Co., --- F. App'x ---- (9th Cir. 2021) may threaten defendan......
  • Ninth Circuit Rejects Challenges To Conjoint Analysis In Consumer Class Action
    • United States
    • Mondaq United States
    • December 30, 2021
    ...569 U.S. 27 (2013), but also that it is inadmissible under Federal Rule of Evidence 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). But a recent Ninth Circuit decision, MacDougall v. American Honda Motor Co., --- F. App'x ---- (9th Cir. 2021) may threaten defendan......
  • Quackery And Junk Science: What It Is, Why It Matters, And How To Spot It
    • United States
    • Mondaq United States
    • May 9, 2022
    ...discussion regarding "junk science" naturally involves the U.S. Supreme Court's decision in Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and its progeny. In Daubert, the "Court focused upon the admissibility of scientific expert testimony [and] pointed out that such te......
  • Request a trial to view additional results
11 books & journal articles
  • Digital Eyewitnesses: Using New Technologies to Authenticate Evidence in Human Rights Litigation.
    • United States
    • Stanford Law Review Vol. 74 Nbr. 4, April 2022
    • April 1, 2022
    ...concrete and objective way to measure the probative value of evidence." (footnote omitted)). (219.) Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579, 592-95, 597 (220.) See Cheng & Nunn, supra note 13, at 1114 (pointing to error rates as one way to ensure the reliability of process-ba......
  • GENDER BIAS IN CROSS-ALLEGATION DOMESTIC VIOLENCE-PARENTAL ALIENATION CUSTODY CASES: CAN STATES LEGISLATE THE FIX?
    • United States
    • Columbia Journal of Gender and Law Vol. 42 Nbr. 1, December 2021
    • December 22, 2021
    ...666; Smith, supra note 49, at 78. (61) See Frye v. United States, 293 F.1013, 1014 (D.C. Cir. 1923); Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579, 580 (1993). See also Frye Standard, CORNELL LAW SCH. LEGAL INFO. INST., https://www.law.cornell.edu/wex/frye_standard [https://perma.cc/LHM......
  • THE RAINBOW CONNECTION: REVISITING THE MIXED-MOTIVE SUMMARY JUDGMENT STANDARD IN BOSTOCK'S AFTERGLOW.
    • United States
    • Fordham Urban Law Journal Vol. 49 Nbr. 4, May 2022
    • May 1, 2022
    ...Rule of Evidence 702)). (292.) See Stone, supra note 159. (293.) See FED. R. CIV. P. 56; see also Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579 (1993) (applying expert testimony admissibility standard to expert affidavits in motion for summary (294.) See Humphreys & Partners Archit......
  • Economic Expert Evidence
    • United States
    • Antitrust Bulletin Nbr. 61-3, September 2016
    • September 1, 2016
    ...juror assessment of yardstick expert testimony to that ofstatistical expert testimony).56. See Daubert v. Merrell Dow Pharms., Inc., 509 U.S. 579 (1993).57. See Kumho Tire Co. v. Carmichael, 526 U.S. 137, 147 (1999) (holding that a court’s gatekeeping function as recognized inDaubert applie......
  • Request a trial to view additional results

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT